disulfiram has been researched along with Prostatic Neoplasms in 16 studies
Prostatic Neoplasms: Tumors or cancer of the PROSTATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Experimental studies have indicated that disulfiram (Antabuse) has antineoplastic effects against melanoma, breast, and prostate cancer." | 3.80 | Use of disulfiram and risk of cancer: a population-based case-control study. ( Askgaard, G; Friis, S; Hallas, J; Pottegård, A; Thygesen, LC, 2014) |
| "Disulfiram was poorly tolerated with six patients experiencing grade 3 adverse events (three per cohort)." | 2.78 | Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer. ( Armstrong, AJ; Bardia, A; Blackford, A; Carducci, MA; King, S; Lin, J; Rudek, MA; Schweizer, MT; Yegnasubramanian, S, 2013) |
| "When genistein was removed, and DSF/Cu was added, the activated currents were small and unstable, and gradually decreased." | 1.72 | Disulfiram-copper activates chloride currents and induces apoptosis with tyrosine kinase in prostate cancer cells. ( Chen, Y; Han, Z; Hou, X; Lei, W; Liang, Y; Xu, J; Ya, Y; Yuan, H; Zha, Z; Zhai, Q; Zhang, J; Zhong, W; Zhou, Y; Zhu, L; Zhuo, Y, 2022) |
| "Castration-resistant prostate cancer (PCa) represents a serious health challenge." | 1.51 | Targeting genotoxic and proteotoxic stress-response pathways in human prostate cancer by clinically available PARP inhibitors, vorinostat and disulfiram. ( Bartek, J; Bartkova, J; Bouchal, J; Cwiertka, K; Gachechiladze, M; Gursky, J; Hodny, Z; Korinkova, G; Kurfurstova, D; Majera, D; Mistrik, M; Simkova, D; Skrott, Z; Steigerova, J, 2019) |
| "Apparently both compounds inhibit prostate cancer cell proliferation by re-expressing the epigenetically repressed tumor-suppressor ER-β through inhibition of DNMT activity." | 1.43 | Disulfiram and its novel derivative sensitize prostate cancer cells to the growth regulatory mechanisms of the cell by re-expressing the epigenetically repressed tumor suppressor-estrogen receptor β. ( Gupta, G; Lal, N; Maikhuri, JP; Mandalapu, D; Porwal, K; Rajender, S; Rawat, T; Sarkar, S; Sharma, V; Sharma, VL; Verma, V; Yadav, SK, 2016) |
| "With the goal of exploiting prostate cancer cell proclivity for copper uptake, we developed a "conditional lethal" screen to identify compounds whose cytotoxic actions were manifested in a copper-dependent manner." | 1.40 | Copper signaling axis as a target for prostate cancer therapeutics. ( Chitneni, SK; Franz, KJ; George, DJ; McDonnell, DP; Nelson, ER; Safi, R; Zalutsky, MR, 2014) |
| "Disulfiram is a non-nucleoside DNMT1 inhibitor that can reduce global (5me)C content, reactivate epigenetically silenced genes, and significantly inhibit growth in prostate cancer cell lines." | 1.37 | Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth. ( Brennen, WN; Britton, J; Carducci, MA; Haffner, MC; Kachhap, SK; Lee, BH; Lin, J; Liu, JO; Nelson, WG; Shim, JS; Yegnasubramanian, S; Zhang, Y, 2011) |
| "Transfection of miR-17* into prostate cancer PC-3 cells significantly reduces levels of the three antioxidant proteins and activity of the luciferase reporter under the control of miR-17* binding sequences located in the 3'-untranslated regions of the three target genes." | 1.36 | miR-17* suppresses tumorigenicity of prostate cancer by inhibiting mitochondrial antioxidant enzymes. ( Fang, F; Josson, S; St Clair, DK; St Clair, WH; Xu, Y; Zhang, J, 2010) |
| "Androgen-independent DU145 and PC-3 prostate cancer cell lines exhibited readily detectable levels of PAM activity in extracts and media, whereas the androgen-dependent LNCaP cell line showed little or no activity." | 1.35 | Catalytically active peptidylglycine alpha-amidating monooxygenase in the media of androgen-independent prostate cancer cell lines. ( Bykowski, CA; Dhananjeyan, M; Ellis, N; Erhardt, PW; Klis, WA; Reese, MD; Sarver, JG; Trendel, JA, 2008) |
| "We then validated DSF as a potential prostate cancer therapeutic agent." | 1.35 | High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth. ( Fey, V; Grafström, RC; Halonen, P; Iljin, K; Kallioniemi, O; Ketola, K; Kohonen, P; Perälä, M; Vainio, P, 2009) |
| "With the extracts of prostates with benign prostatic hyperplasia the pI 4." | 1.28 | Human prostatic aldehyde dehydrogenase of healthy controls and diseased prostates. ( Ambroziak, W; Ryzlak, MT; Schaffner, CP, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 11 (68.75) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Mahani, M | 1 |
| Montazer, L | 1 |
| Khakbaz, F | 1 |
| Divsar, F | 1 |
| Yoosefian, M | 1 |
| Lei, W | 1 |
| Xu, J | 1 |
| Ya, Y | 1 |
| Zhang, J | 2 |
| Hou, X | 1 |
| Zhai, Q | 1 |
| Zha, Z | 1 |
| Zhuo, Y | 1 |
| Zhou, Y | 1 |
| Yuan, H | 1 |
| Liang, Y | 1 |
| Han, Z | 1 |
| Zhong, W | 1 |
| Zhu, L | 1 |
| Chen, Y | 1 |
| Majera, D | 1 |
| Skrott, Z | 1 |
| Bouchal, J | 1 |
| Bartkova, J | 1 |
| Simkova, D | 1 |
| Gachechiladze, M | 1 |
| Steigerova, J | 1 |
| Kurfurstova, D | 1 |
| Gursky, J | 1 |
| Korinkova, G | 1 |
| Cwiertka, K | 1 |
| Hodny, Z | 1 |
| Mistrik, M | 1 |
| Bartek, J | 1 |
| Askgaard, G | 1 |
| Friis, S | 1 |
| Hallas, J | 1 |
| Thygesen, LC | 1 |
| Pottegård, A | 1 |
| Schweizer, MT | 1 |
| Lin, J | 2 |
| Blackford, A | 1 |
| Bardia, A | 1 |
| King, S | 1 |
| Armstrong, AJ | 1 |
| Rudek, MA | 1 |
| Yegnasubramanian, S | 2 |
| Carducci, MA | 2 |
| Safi, R | 1 |
| Nelson, ER | 1 |
| Chitneni, SK | 1 |
| Franz, KJ | 1 |
| George, DJ | 1 |
| Zalutsky, MR | 1 |
| McDonnell, DP | 1 |
| Thoma, C | 1 |
| Ren, J | 1 |
| Huang, H | 1 |
| Liu, Y | 1 |
| Zheng, X | 1 |
| Zou, Q | 1 |
| Sharma, V | 1 |
| Verma, V | 1 |
| Lal, N | 1 |
| Yadav, SK | 1 |
| Sarkar, S | 1 |
| Mandalapu, D | 1 |
| Porwal, K | 1 |
| Rawat, T | 1 |
| Maikhuri, JP | 1 |
| Rajender, S | 1 |
| Sharma, VL | 1 |
| Gupta, G | 1 |
| Trendel, JA | 1 |
| Ellis, N | 1 |
| Sarver, JG | 1 |
| Klis, WA | 1 |
| Dhananjeyan, M | 1 |
| Bykowski, CA | 1 |
| Reese, MD | 1 |
| Erhardt, PW | 1 |
| Iljin, K | 2 |
| Ketola, K | 2 |
| Vainio, P | 1 |
| Halonen, P | 1 |
| Kohonen, P | 1 |
| Fey, V | 1 |
| Grafström, RC | 1 |
| Perälä, M | 1 |
| Kallioniemi, O | 2 |
| Haffner, MC | 1 |
| Zhang, Y | 1 |
| Lee, BH | 1 |
| Brennen, WN | 1 |
| Britton, J | 1 |
| Kachhap, SK | 1 |
| Shim, JS | 1 |
| Liu, JO | 1 |
| Nelson, WG | 1 |
| Xu, Y | 1 |
| Fang, F | 1 |
| Josson, S | 1 |
| St Clair, WH | 1 |
| St Clair, DK | 1 |
| O'Brien, A | 1 |
| Barber, JE | 1 |
| Reid, S | 1 |
| Niknejad, N | 1 |
| Dimitroulakos, J | 1 |
| Ryzlak, MT | 1 |
| Ambroziak, W | 1 |
| Schaffner, CP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Open Labeled Trial of Disulfiram With Copper in Metastatic Breast Cancer[NCT03323346] | Phase 2 | 150 participants (Anticipated) | Interventional | 2017-09-29 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for disulfiram and Prostatic Neoplasms
| Article | Year |
|---|---|
Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer.
Topics: Aged; Antineoplastic Agents; Ceruloplasmin; Disulfiram; DNA Methylation; Epigenesis, Genetic; Humans | 2013 |
15 other studies available for disulfiram and Prostatic Neoplasms
| Article | Year |
|---|---|
Photothermal performance of a novel carbon dot and its conjugate with disulfiram for prostate cancer PC3 cell therapy.
Topics: Carbon; Cell- and Tissue-Based Therapy; Copper; Disulfiram; Humans; Male; Prostatic Neoplasms; Quant | 2023 |
Disulfiram-copper activates chloride currents and induces apoptosis with tyrosine kinase in prostate cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Chloride Channels; Chlorides; Copper; Disulfiram; Genistein; Humans; Ma | 2022 |
Targeting genotoxic and proteotoxic stress-response pathways in human prostate cancer by clinically available PARP inhibitors, vorinostat and disulfiram.
Topics: Cell Line, Tumor; Disulfiram; DNA Repair; Gene Expression Regulation, Neoplastic; Humans; Male; Mole | 2019 |
Use of disulfiram and risk of cancer: a population-based case-control study.
Topics: Aged; Alcohol Deterrents; Breast Neoplasms; Case-Control Studies; Denmark; Disulfiram; Female; Human | 2014 |
Copper signaling axis as a target for prostate cancer therapeutics.
Topics: Androgens; Animals; Antineoplastic Agents; Apoptosis; Biological Transport; Cell Line, Tumor; Copper | 2014 |
Prostate cancer: copper unlocks therapeutic potential of disulfiram.
Topics: Animals; Antineoplastic Agents; Copper; Disulfiram; Humans; Male; Prostatic Neoplasms; Signal Transd | 2014 |
An Atomic Force Microscope Study Revealed Two Mechanisms in the Effect of Anticancer Drugs on Rate-Dependent Young's Modulus of Human Prostate Cancer Cells.
Topics: Amino Acids; Celecoxib; Cell Line, Tumor; Cytoskeleton; Disulfiram; Elastic Modulus; Fluorescent Ant | 2015 |
Disulfiram and its novel derivative sensitize prostate cancer cells to the growth regulatory mechanisms of the cell by re-expressing the epigenetically repressed tumor suppressor-estrogen receptor β.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disulfiram; Enzyme Inhibitors; Epigene | 2016 |
Catalytically active peptidylglycine alpha-amidating monooxygenase in the media of androgen-independent prostate cancer cell lines.
Topics: Animals; Cell Line, Tumor; Culture Media; Disulfiram; Dopamine; Enzyme Inhibitors; Humans; Male; Mix | 2008 |
High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies disulfiram as an inhibitor of prostate cancer cell growth.
Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Proliferation; Cells, Cultured; Disulfiram; Drug Scr | 2009 |
Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Disulfiram; DNA (Cytosine-5-)-Methyltransferase 1; DN | 2011 |
miR-17* suppresses tumorigenicity of prostate cancer by inhibiting mitochondrial antioxidant enzymes.
Topics: Antioxidants; Carbamates; Cell Line, Tumor; Disulfiram; Gene Expression Regulation, Neoplastic; Glut | 2010 |
Enhancement of cisplatin cytotoxicity by disulfiram involves activating transcription factor 3.
Topics: Activating Transcription Factor 3; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; C | 2012 |
Chemical biology drug sensitivity screen identifies sunitinib as synergistic agent with disulfiram in prostate cancer cells.
Topics: Apoptosis; Cadherins; Cell Line, Tumor; Cell Movement; Cell Survival; Disulfiram; Drug Screening Ass | 2012 |
Human prostatic aldehyde dehydrogenase of healthy controls and diseased prostates.
Topics: Aged; Aldehyde Dehydrogenase; Aldehydes; Blotting, Western; Cytosol; Disulfiram; Glutathione Transfe | 1992 |